ReviewLeukemia2022
A comprehensive review of the impact of obesity on plasma cell disorders.
Review in Leukemia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06987708 (Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers Associated With Monoclonal Gammopathy of Unknown Significance), which is not on this map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers Associated With Monoclonal Gammopathy of Unknown Significance (MGUS) and Smoldering Myeloma (SM): A Prospective Intervention Pilot Study
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Correlation Between Bariatric Surgery and the Risk of Multiple Myeloma: Results from an Evidence-Based Strategy.Obesity surgery · 2024Pooled it
- Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.The New England journal of medicine · 2022Trial
- Obesity Accelerates Multiple Myeloma Progression in Certain Mouse Models and in Humans.Cancer prevention research (Philadelphia, Pa.) · 2026Article
- Microenvironmentally derived fatty acid-binding proteins 4 and 5 are novel therapeutic vulnerabilities in multiple myeloma.Blood neoplasia · 2026Article
- Diabetes mellitus in multiple myeloma and related plasma cell disorders: a review of risk, prognosis, and outcomes.Blood cancer journal · 2026Review
- A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model.Cancer discovery · 2026Article
- Dietary patterns among individuals with plasma cell disorders- opportunities for targeted interventions.Blood cancer journal · 2026Article
- Racial differences in the proportion of myeloma cases attributable to excess body weight and diabetes mellitus in the United States.Haematologica · 2026Article
- Burden of Hematological Malignancies in East Asia from 1990 to 2021.Journal of clinical medicine · 2025Article
- Food for Thought: Addressing a Research Gap for Dietary Trials in Hematologic Malignancies.Blood cancer discovery · 2025Article
- Prediagnostic Serum Immune Marker Levels and Multiple Myeloma: A Prospective Longitudinal Study Using Samples from the Janus Serum Bank in Norway.Cancer prevention research (Philadelphia, Pa.) · 2025Article
- Effect of adipose tissue on the development of multiple myeloma.Molecular biology reports · 2024Review
- Association between glucagon-like peptide-1 receptor agonist use and progression of monoclonal gammopathy of uncertain significance to multiple myeloma among patients with diabetes.JNCI cancer spectrum · 2024Article
- Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis.Leukemia · 2024Article
- Adipocytes and metabolism: Contributions to multiple myeloma.Journal of bone oncology · 2024Article
- Diet-induced obesity reduces bone marrow T and B cells and promotes tumor progression in a transplantable Vk*MYC model of multiple myeloma.Scientific reports · 2024Article
- Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups.Blood advances · 2024Article
- Causal associations between the gut microbiota and multiple myeloma: a two-sample Mendelian randomization study.Frontiers in nutrition · 2024Article
- Non-Toxicological Role of Aryl Hydrocarbon Receptor in Obesity-Associated Multiple Myeloma Cell Growth and Survival.Cancers · 2023Article
- It is worth the weight: obesity and the transition from monoclonal gammopathy of undetermined significance to multiple myeloma.Blood advances · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
Abstract
Multiple myeloma (MM) remains an incurable plasma cell malignancy. Although little is known about the etiology of MM, several metabolic risk factors such as obesity, diabetes, poor nutrition, many of which are modifiable, have been linked to the pathogenesis of numerous neoplasms including MM. In this article, we provide a detailed summary of what is known about the impact of obesity on the pathogenesis of MM, its influence on outcomes in MM patients, and discuss potential mechanisms through which obesity is postulated to influence MM risk and prognosis. Along with advancements in treatment modalities to improve survival in MM patients, focused efforts are needed to prevent or intercept MM at its earliest stages. The consolidated findings presented in this review highlight the need for clinical trials to assess if lifestyle modifications can reduce the incidence and improve outcomes of MM in high-risk populations. Data generated from such studies can help formulate evidence-based lifestyle recommendations for the prevention and control of MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.